Determination of risperidone and 9-hydroxyrisperidone in human plasma by high-performance liquid chromatography: application to therapeutic drug monitoring in Japanese patients with schizophrenia.

[1]  D. Hoffman,et al.  Therapeutic drug monitoring of risperidone and 9-hydroxyrisperidone in serum with solid-phase extraction and high-performance liquid chromatography. , 1997, Therapeutic drug monitoring.

[2]  L. Bertilsson,et al.  Polymorphic Drug Oxidation , 1996 .

[3]  P. Bonaventure,et al.  In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: risperidone compared with antipsychotics hitherto used. , 1995, Japanese journal of pharmacology.

[4]  N. Yasui,et al.  High‐performance Liquid Chromatographic Determination of Trazodone and 1‐m‐Chlorophenylpiperazine with Ultraviolet and Electrochemical Detector , 1995, The Journal of pharmacy and pharmacology.

[5]  S. Marder,et al.  Risperidone in the treatment of schizophrenia. , 1994, The American journal of psychiatry.

[6]  A. Peer,et al.  Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects , 1993, Clinical pharmacology and therapeutics.

[7]  S. Marder,et al.  Determination of risperidone in plasma by high-performance liquid chromatography with electrochemical detection: application to therapeutic drug monitoring in schizophrenic patients. , 1993, Journal of pharmaceutical sciences.

[8]  M. Ingelman-Sundberg,et al.  Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population , 1992, Clinical pharmacology and therapeutics.

[9]  C J Niemegeers,et al.  Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. , 1988, The Journal of pharmacology and experimental therapeutics.